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Abstract 
Background: The short (‘S’) allele of the serotonin transporter (5-HTT)-linked 
polymorphic region (5-HTTLPR) is associated with increased negative emotion 
processing bias, and this polymorphism moderates acute effects of selective serotonin 
reuptake inhibitor (SSRI) treatment. Here In this preliminary study, we explore the 
moderating effect of 5-HTTLPR on the impact of the SSRI, escitalopram during 
emotion regulation of negative emotional stimuli. 
Method: Thirty-six healthy Caucasian, female participants underwent two fMRI 
scanning sessions following single dose escitalopram and placebo administration 
separated by a seven-day washout period according to a double-blind, randomized, 
placebo-controlled crossover design. Functional connectivity analysis was employed 
with a left (L) amygdala seed and a right interior frontal gyrus (R IFG) target.  
Results: Changes in functional connectivity with emotion regulation and treatment were 
linearly related to 5-HTTLPR ‘L’ allele load such that negative R IFG-L amygdala 
connectivity was increased with an increasing number of ‘L’ alleles. Therefore, 
escitalopram may facilitate the effects of reappraisal by enhancing negative functional 
connectivity, a finding that is greatest in participants homozygous for the ‘L’ allele and 
least in those homozygous for the ‘S’ allele.  
Limitations: Sub-samples of the homozygote ‘S/S’ and ‘L/L’ 5-HTTLPR groupings 
were small. However, the within-subjects nature of the experiment and observing 
changes at the individual subject level increases our confidence in the findings of the 
present study. 
Conclusions: The present study elucidates a potential neural mechanism by which 
antidepressant treatment produces differential treatment outcomes dependent on the 5-
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HTTLPR polymorphism, providing new and important leads for models of 
antidepressant action. 
Keywords: antidepressant; 5-HTTLPR; emotion; serotonin; pharmacogenetics; fMRI 
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1. Introduction 
Affective disorders including major depressive disorder and generalized anxiety 
disorder are common disabling conditions, associated with a high degree of burden 
(World Health Organization, 2008). Key underlying cognitive deficits of these disorders 
are negative emotion processing bias—whereby reactivity to negative emotional stimuli 
is greater than that to positive stimuli—and dysfunctional emotion dysregulation are key 
(Beck, 2008; Beck et al., 1979; Gotlib and Joormann, 2010). Together, these deficits 
reduce inhibition of negatively-valenced emotional stimuli. Antidepressant medication 
has been shown to ameliorate these deficiencies by decreasing negative emotion 
processing bias (Harmer, 2012) and facilitating adaptive emotion regulation strategies, 
namely reappraisal (McRae et al., 2014), which is an emotion regulation strategy that 
involves reframing of a situation or stimulus to decrease resultant emotional reactivity 
(Gross, 1998; Gross and Thompson, 2007). However, the variability of therapeutic 
response with antidepressant treatment is high, with 50% to 70% of patients not 
responding to first-line treatment (Kemp et al., 2015; 2008; Trivedi, 2006). Previous 
research on genetic variation at the serotonin transporter-linked promoter region (5-
HTTLPR) explains variation in amygdala activity changes associated with decreased 
negative emotion processing bias with a single dose of the commonly prescribed SSRI 
escitalopram (Outhred et al., 2014a) and citalopram (Ma et al., 2015). We have also 
observed that a single dose of escitalopram facilitates the activity of a key neural 
pathway involved in reappraisal (Outhred et al., 2015). In the present paper, we 
investigate whether facilitation of this reappraisal neural pathway with escitalopram is 
modulated by 5-HTTLPR variation. In doing so, the present paper will contribute to 
understanding the association between 5-HTTLPR and SSRI response and remission 
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rates (Huezo-Diaz et al., 2009; Kato and Serretti, 2010; Licinio and Wong, 2011; 
Serretti et al., 2007; Smeraldi et al., 1998). 
The serotonin transporter protein (5-HTT) is the key target of commonly 
prescribed selective serotonin reuptake inhibitors (SSRIs; Klein et al., 2006). 5-HTT is 
encoded by the gene SLC6A4, the expression of which is modulated by a polymorphism 
in the promoter region, termed 5-HTTLPR (Del-Ben et al., 2005; Heils et al., 1996; 
Lesch et al., 1996). The short (‘S’) allele of the 5-HTTLPR is associated with lower 
transcriptional efficiency of 5-HTT as compared to the long (‘L’) allele, leading to 
dysfunctional regulation of 5-HT (Canli and Lesch, 2007; Heils et al., 1996; Lesch et 
al., 1996; Lesch and Gutknecht, 2005; Smeraldi et al., 1998). Previous research has 
shown that, in comparison to ‘L’ allele carriers, ‘S/S’ homozygotes display lower 
remission and response rates when treated with SSRIs (Kato and Serretti, 2010; Licinio 
and Wong, 2011; Serretti et al., 2007).  
Although specific cellular mechanisms remain to be illustrated, it is known the 
‘S’ allele is associated with chronic dysregulation of 5-HT with depletion occurring 
with little reuptake after release as well as 5-HT1A autoreceptor over-sensitivity 
resulting in little release overtime (Hariri et al., 2005; Risch et al., 2009). Hence, SSRI 
treatment at the acute stage leads to further dysregulation, reducing 5-HT availability in 
the synapse (Ruhé et al., 2009). This may be due to reduced maintenance of 5-HT pools 
in presynaptic neurons for subsequent release as ‘S’ allele has half the 5-HT reuptake 
(Lesch et al., 1996), which may then increase 5-HT1A autoreceptor sensitivity (Smeraldi 
et al., 1998) leading to decreased 5-HT availability in the synapse (Canli and Lesch, 
2007; Lesch and Gutknecht, 2005). One potential mechanism is that the acute action of 
SSRIs in ‘S’ carriers may further decrease 5-HT availability in the synapse under 5-
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HTT blockade through increased negative feedback from increased 5-HT1A autoreceptor 
sensitivity when 5-HT remains in the synapse after release (Celada et al., 2013). An 
alternative mechanism is that the low 5-HT pools in ‘S’ carriers become more exhausted 
with decreased reuptake with SSRI blockade, leading to further decreases in 5-HT 
availability in the synapse (Ruhé et al., 2009). Regardless, 5-HTT blockade with SSRIs 
in ‘S’ carriers is associated with worsening treatment outcome due to increased 5-HT 
dysregulation (Ruhé et al., 2009).  
Our previous work demonstrated that single-dose SSRI treatment modulates 
neural activity by supressing negative emotion processing biases (Kemp et al., 2004a; 
Outhred et al., 2014b; 2013), and that variability in this effect is explained by 5-
HTTLPR allelic variation in a dose-response manner (Outhred et al., 2014a). In this 
study, we found that ‘S/S’ homozygote neural responses to affective pictorial stimuli 
were associated with increased negative emotion bias and ‘L/L’ homozygote neural 
responses were associated with decreased negative emotion bias with SSRI treatment 
(Outhred et al., 2014a). This finding has been independently corroborated with 
experiments employing the SSRI citalopram and affective facial stimuli (Ma et al., 
2015). In the context of prior research (Kato and Serretti, 2010; Licinio and Wong, 
2011; Serretti et al., 2007), these findings may have important implications for 
understanding the variation in response rates explained, at least in part, by the impact of 
5-HTTLPR on acute treatment effects on emotion processing and emotion regulation. 
Hariri and Holmes (2006) implicate 5-HTTLPR in the integrity of the functional 
pathway between the prefrontal cortex and the amygdala, such that ‘S’ allele carriers are 
characterised by diminished inhibitory emotion regulation feedback. Negative 
functional connectivity between right inferior frontal gyrus (R IFG) and left (L) 
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amygdala during reappraisal reflects regulation of neural responses to negative stimuli 
(Aron et al., 2004; Banks et al., 2007; Goldin et al., 2008; Ochsner and Gross, 2005). 
Heinz and colleagues (2005) found positive amygdala and prefrontal coupling during 
negative images in ‘S’ allele carriers than ‘L/L’ homozygotes, with no association 
observed for positive images. These authors suggested that the ‘S’ allele is associated 
with increased risk of psychopathology due to dysfunctional amygdala-prefrontal 
connectivity within emotion regulation pathways during the processing of negative 
stimuli, increasing the saliency of the stimuli (Heinz et al., 2005). More recently, we 
observed that a single dose of escitalopram is associated with negative L amygdala-R 
IFG coupling during reappraisal of negative stimuli, suggesting facilitation of emotion 
regulation within this pathway (Outhred et al., 2015). However, it remains unclear 
whether allelic variation in 5-HTTLPR moderates this effect. 
Building on our previous findings (Outhred et al., 2014a) and the 5-HTT 
literature showing that ‘L’ carriers have better treatment outcomes than ‘S’ carriers both 
at the cellular and the behavioral levels, we predicted a linear relationship (dose-
response) between 5-HTTLPR and L amygdala-R IFG functional connectivity during 
the reappraisal of negative images after single dose escitalopram relative to placebo. 
Given that SSRI treatment is associated with increased dysregulation in ‘S/S’ allele 
homozygotes (Outhred et al., 2014a), we hypothesise that ‘S/S’ allele carriers will 
display more positive L amygdala-R IFG coupling than ‘L/L’ homozygotes during 
reappraisal of negative stimuli under escitalopram. 
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2. Methods 
2.1 Participants 
Thirty-six right-handed healthy Caucasian female participants (mean age = 
25.08; SD = 6.49; range 18-47) were recruited and completed a trial, as previously 
reported (Outhred et al., 2015; 2014b; 2014a). The present study interrogates the genetic 
and fMRI findings on an emotion regulation task we employed (an event-related design 
with reappraisal of negative images). Our previous paper (Outhred et al., 2015) reports 
on the basic emotion regulation effects and our other papers (Outhred et al., 2014b; 
2014a) reported on fMRI findings from a basic emotion processing task (a blocked 
design viewing negative, positive, and neutral images). Hence, the genetic effects on the 
emotion regulation task results have not been previously reported. All participants 
provided informed consent in accordance with the Australian National Health and 
Medical Research Council (NHMRC) guidelines. The Sydney University Human 
Research Ethics Committee (13901) and the Northern Sydney Central Coast Area 
Health Service Human Research Ethics Committee (1105-178M) granted ethical 
approval for this study. This trial was also registered with the Australian New Zealand 
Clinical Trials Registry (ANZCTR, available here: http://www.anzctr.org.au; 
ACTRN12611000719932). Participants were determined to be free from medication 
(other than hormonal contraceptives), physical and psychiatric illness, major depressive 
disorder (PHQ-9 assessment; Kroenke et al., 2001) or generalized anxiety disorder 
symptoms (GAD-7 assessment; Spitzer et al., 2006). Additionally, participants were 
free from illicit drug use and heavy alcohol use (abstaining for at least 24 hours), 
smoking, brain injury, neurological disorders, loss of consciousness for longer than five 
minutes, and contraindications for fMRI scanning. Finally, participants abstained from 
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caffeine on the morning of the experiment and no participant tested positive on 
pregnancy tests conducted at each session. See Table 1 for a breakdown of participant 
demographics by 5-HTTLPR grouping with statistical tests showing no between group 
differences. 
2.2 Genotyping 
DNA was extracted from saliva samples and 5-HTTLPR and rs25531 genotypes 
were determined, given the differential impact of the La and Lg genotypes (Dannlowski 
et al., 2007; Hu et al., 2005; Kato et al., 2013). The Lg variant of rs25531 and the ‘S’ 5-
HTTLPR allele are similar in function; thus, the Lg variant is considered low expressing 
(Hu et al., 2005). 5-HTTLPR and rs25531 were determined according to protocols 
described previously (Bryant et al., 2010; Quinn et al., 2012). Genotypes were scored 
independently by two researchers. See the Supplement for 5-HTTLPR and rs25531 
grouping number breakdowns. To summarize, the functional 5-HTTLPR genotypes 
(taking into account rs225531) were categorized as ‘S/S’ (n = 8; 22%), ‘S/L’ (n = 21; 
58%), and ‘L/L’ (n = 7; 19%), and were found to be in Hardy-Weinberg equilibrium, χ2 
(1) = 1.011, p = 0.315. 
2.3 Experimental and Emotion Regulation Task design 
All participants were tested under placebo (saccharin) and escitalopram (20 mg; 
per os) conditions using a randomized, double-blind, placebo controlled cross-over 
design, with a washout period of one week (or five half-lives t1/2 = 26.7 hours; 
Alphapharm, 2012; Sogaard et al., 2005). A crossover design and checks for correct 
experimental manipulation (instead of a mixed-models approach) were used, as 
previously recommended and discussed (Mills et al., 2009; Senn et al., 2004). An equal 
number of participants had either treatment in their first testing session. fMRI during an 
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emotion regulation task was conducted four hours post-treatment to coincide with 
expected peak pharmacokinetic effects of escitalopram (mean tmax = 4.0 hours, tmax = 
3.0 ± 1.5 hours; Alphapharm, 2012; Sogaard et al., 2005). An event-related emotion 
regulation task was constructed with instruction prompts (‘Think Objectively’; 
‘Watch’), high-arousal negative valance pictures, low-arousal neutral valance pictures, a 
negative valence rating scale prompt, an arousal rating scale prompt, and fixation 
crosses (see Supplement). This task was based on that used by Goldin and colleagues 
(Goldin et al., 2008). Stimuli were selected from the International Affective Picture 
System (Lang et al., 2008), based on the normed valence and arousal ratings that are 
provided in the IAPS manual. The task consisted of trials with a 2-second instruction 
(either ‘Think Objectively’ or ‘Watch’) followed by a 4-second high arousal negative 
IAPS image, a 2-second negative valence rating, a 2-second arousal rating, a 2-second 
‘Watch’ instruction, a 4-second low arousal neutral IAPS image, and a jittered fixation 
cross (average duration of 4 seconds; see Supplement for further details on the task 
administered to participants). The valence and arousal rating scales were on a five-point 
scale from “0. ‘not at all negative/arousing’” to “4.‘overwhelmingly 
negative/arousing’”. During the ‘Think Objectively’ trials, participants were asked to 
assume the perspective of a medical professional watching an instructional video, 
focusing on technical aspects of the film, so as to decrease emotional reactivity as per 
previously published study (Goldin et al., 2008). During the ‘Watch’ trials, participants 
were asked to view the negative image and to ‘feel’ the emotions associated with each 
of the pictures. Attention to experiencing the emotional stimuli applies to both the 
‘Watch’ and ‘Think Objectively’ conditions. In the ‘Think Objectively’ condition, 
however, participants are asked to reappraise the stimuli in order to decrease emotional 
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reactivity. Therefore, the contrast between the two conditions allows for neural changes 
associated with thinking objectively about the stimuli to be determined, by partialling 
out the attention to the experience component. Analysis of the behavioral valence and 
arousal ratings (see Supplement) demonstrated that the ‘Think Objectively’ condition 
successfully reduced emotional reactivity to the stimuli relative to the ‘Watch’ 
condition, providing an important validation of the task on which neural changes were 
determined. 
A variety of hormonal, behavioral, and neurophysiological manipulation checks 
were performed. Analyses revealed that our results reported below were not confounded 
by side effects or menstrual phase (see Supplement). 
2.4 fMRI data acquisition 
Using a 3.0 T Siemens Trio scanner, imaging was performed at Advanced 
Research and Clinical Highfield Imaging (ARCHI, the University of Sydney; a 
dedicated research facility). Twenty-nine consecutive axial slices (4 mm thickness with 
1 mm gap) parallel to the anterior–posterior commissure covering the whole brain were 
imaged using a T2*-weighted gradient echo EPI sequence (echo time [TE] = 32 ms; 
repetition time [TR] = 2000 ms; matrix = 64 × 64; flip angle = 70°). The field of view 
was 240 mm and the effective in plane functional spatial resolution was 3.75 mm. For 
each functional run, 305 volumes were collected, after which the first five were 
discarded to allow for magnetic saturation effects. Participant movement was minimised 
by securing the head within the scanner coil using foam padding. 
2.5 fMRI data analyses 
The imaging data from the two treatment sessions were inspected, pre-processed 
and analyzed using standard image processing routines implemented within the 
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statistical parametric mapping software package, SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8/; Wellcome Trust Centre for 
Neuroimaging). Images for each subject were realigned (and unwarped) and spatially 
normalized into a standard stereotactic space (Montreal Neurologic Institute template) 
and smoothed with a Gaussian kernel (FWHM 8 mm) in order to minimize anatomical 
differences, and slice timing correction was performed. Realignment parameters were 
inspected and subjects had movement less than the size of a voxel of 3.75 mm, thus no 
data was considered to be problematic. The BOLD response at each voxel was modelled 
with a canonical hemodynamic response function and its temporal derivative, with the 
events reappraise negative and watch negative events modelled across each session and 
all other trials events modelled as baseline, along with realignment regressors of no 
interest. The default high-pass filter of 128 seconds was applied and did not cut off 
experimental variance. Generalized Psychophysiological Interaction analysis (gPPI; 
McLaren et al., 2012) was conducted to determine experimental condition dependent 
functional connectivity. Following gPPI routines, the deconvolved time series from a 
functionally derived L amygdala seed region (drawn as a sphere 6 mm in radius at 
previously identified coordinates [-20, -4, -20]; Outhred et al., 2015) was extracted to 
create the physiological variable for each participant. Though it would have been 
possible to examine the right amygdala in another analysis, this would be based on the 
assumption that the activation is the same on the right side. To avoid relying on this 
assumption and creating further multiple comparisons issues, we restricted our analysis 
to an ROI guided by our previous findings with the left amygdala (Outhred et al., 2015; 
2014b). Though we did not intend to test a laterality hypothesis, prior studies show a 
consistent pattern of left amygdala lateralization in emotional processing (Baas et al., 
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2004). Selection of the L amygdala, over the R IFG, as a seed region is consistent with 
previous research (Banks et al., 2007; Foland et al., 2008; Kanske et al., 2011; Payer et 
al., 2012; Townsend et al., 2013). Furthermore, the L amygdala-R IFG functional 
connectivity estimate has shown robust modulation with reappraisal (Aron et al., 2004; 
Buhle et al., 2014; Goldin et al., 2008; Ochsner and Gross, 2005; Ochsner et al., 2012) 
and treatment administration (Kemp et al., 2004a; Outhred et al., 2015; 2014b; 2014a; 
2013). The condition onset times for the ‘reappraise negative’ and ‘watch negative’ 
events under each treatment session were each convolved with the canonical 
hemodynamic response function, creating two task regressors for each treatment 
session. The physiological variable and the ‘reappraise negative’ (and ‘watch negative’ 
task) regressors were then multiplied to obtain the ‘reappraise negative’ (and ‘watch 
negative’) PPIs. These two PPIs were contrasted each participant, with the resultant 
contrast representing reappraisal-associated modulation of functional connectivity. Thus 
each participant had contrasts for reappraisal-associated modulation of functional 
connectivity for each treatment session. In order to extract estimates of the direction and 
magnitude of functional connectivity, beta coupling estimates for participants’ 
reappraisal PPI contrasts for each treatment session were extracted from the R IFG 
region using the MarsBaR toolbox (Brett et al., 2002) for the following analyses. For 
reference, results of the previously reported regions of interest analyses (an a priori R 
IFG analysis, and a wider frontal region analysis for illustration of connectivity with 
other regulatory regions) and the functional connectivity (gPPI) analysis are provided in 
the Supplement, and are reported and discussed in detail in our previous work (Outhred 
et al., 2015). Hence, we extended these analyses in the present study to determine the 
between-subjects effects of 5-HTTLPR allele loading on the effect of escitalopram on 
5-HTTLPR, Escitalopram, and Emotion Regulation 16 
reappraisal using the previously determined coupling estimates. For illustrative 
purposes only, averaged beta coupling estimates for each treatment session are 
presented in Figure 1C, alongside those split and averaged for each 5-HTTLPR group. 
In this context, negative functional connectivity indicates that decreases in L amygdala 
activity are correlated with (not caused by) increases in R IFG activity under reappraisal 
(a relationship that is associated with effective emotion regulation during reappraisal), 
where as positive functional connectivity indicates increases in L amygdala activity are 
correlated with increases in R IFG (a relationship that is associated with ineffective 
emotion regulation during reappraisal). 
For the present study, the PPI beta coupling estimates from each participant at 
the escitalopram session was subtracted from those of the placebo session. The resultant 
values represented the within-subjects relative change in L amygdala-R IFG functional 
connectivity with escitalopram treatment during reappraisal relative to placebo, with 
positive beta coupling change values representing increased connectivity with treatment 
relative to placebo. As 5-HTTLPR allele loading prediction is consistent with a dosage 
model of 5-HTT expression (Caspi et al., 2003; Freidlin et al., 2002), it is a common 
data analysis strategy (Hariri et al., 2005; Outhred et al., 2014a; Risch et al., 2009). 
Consequently, linear regressions were performed in IBM SPSS 21 for OSX with 5-
HTTLPR ‘L’ allele loading as a predictor variable and the beta coupling change values 
as a dependent variable. For the purposes of this study, 5-HTTLPR allele loading 
prediction was performed in order to illustrate and determine the extent of the effect of 
5-HTTLPR allele loading has on modulation of functional connectivity between the L 
amygdala-R IFG functional connectivity during reappraisal with escitalopram. For 
verification purposes, this linear regression analysis was supported on a background of a 
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significant analysis of variance (ANOVA) testing for 5-HTTLPR group differences on 
the PPI beta coupling change values, F(2, 33) = 12.792, p < 0.001, partial η2 = 0.437. 
Significant behavioral analysis on modulation functional connectivity during reappraisal 
with escitalopram was previously reported, but was not significant for 5-HTTLPR group 
differences. In order to illustrate that the regression models are consistent with the 
aforementioned 5-HTT expression dose-response model, Cook’s Distances (Cook and 
Weisberg, 1982) were calculated for each data point. The Cook’s Distance values were 
checked for values greater than one, which would indicate data points that have a 
specific influence on (or drove the significance of) the determined regression slope. In 
order to determine whether any 5-HTTLPR group had a specific influence on—or had a 
significantly greater loading, thereby driving significance of—the determined regression 
slopes, one-way ANOVAs were performed on the Cook’s Distance values from each 
regression slope and checked for significant differences between 5-HTTLPR groups.  
3. Results 
3.1 fMRI results: 5-HTTLPR on functional connectivity (gPPI) with 
reappraisal for escitalopram and placebo sessions 
Functional connectivity (gPPI) results are displayed in Figure 1. For illustrative 
purposes only, the average gPPI beta coupling estimates between the L amygdala 
(Figure 1A) and R IFG (Figure 1B) for the escitalopram and placebo sessions for the 
whole sample (N = 36; as previously reported) are shown along side those across each 
5-HTTLPR group (‘S/S’, ‘S/L’, ‘L/L’; Figure 1C for the present report). For the whole 
sample, negative functional connectivity (decreased L amygdala activity paired with 
increased R IFG activity) was heightened with escitalopram, relative to placebo. 
Descriptively, differential responses were observed when the sample was split by 5-
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HTTLPR groups (‘S/S’, ‘S/L’, ‘L/L’; see Figure 1C). In the ‘S/S’ group, functional 
connectivity was positive under placebo and this positive connectivity was heightened 
with escitalopram administration. The ‘S/L’ group displayed positive functional 
connectivity under placebo and showed negative functional connectivity with 
escitalopram. Finally, the ‘L/L’ group showed negative functional connectivity under 
placebo, which was heightened with escitalopram. 
3.2 fMRI results: 5-HTTLPR on functional connectivity (gPPI) during 
reappraisal with escitalopram 
The linear regression on the gPPI beta coupling change values with 5-HTTLPR 
grouping as the predictor was significant, r2 = 0.324, adjusted r2 = 0.304, F(1, 34) = 
16.277, p < 0.001. Descriptively, this observation suggests that under escitalopram, an 
increasing number of ‘L’ alleles is associated with increasing negative L amygdala-R 
IFG functional connectivity during reappraisal. In turn, this finding suggests that 
escitalopram facilitates the effects of ‘L’ alleles by enhancing negative functional 
connectivity during reappraisal. See Figure 1D for a visualisation of this result. 
Consistent with a dose-response model, no data point was significantly influential (all 
Cook’s Distances < 1) and no 5-HTTLPR group was specifically influential on the 
determined regression slope (F[2, 33] = 1.615, p = 0.214). 
4. Discussion 
The present study examined the impact of 5-HTTLPR on neural responses 
during reappraisal of highly arousing negative pictures after a single dose of 
escitalopram. Consistent with predictions, 5-HTTLPR allelic variation accounted for 
significant variance (adjusted r2 = 0.304) in the functional connectivity between the L 
amygdala and the R IFG during reappraisal under escitalopram. Specifically, with 
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increasing number of ‘L’ alleles, the negative functional connectivity between these 
regions was increased. With escitalopram treatment, the functional connectivity in the 
‘S/S’ group was more positive, the ‘S/L’ group was more negative, and the ‘L/L’ group 
was more negative further still (as illustrated in Figure 1D). Though preliminary, these 
findings suggest that 5-HTTLPR may influence the acute effects of an SSRI through 
facilitation of the functional connections between the L amygdala and R IFG during 
reappraisal. Such responses may underlie changes in emotional bias and have 
consequences for therapeutic effects (see Figure 2). 
Building on our earlier pharmaco-fMRI findings (Outhred et al., 2015; 2014b; 
2013) and previous pharmacogenetic-fMRI study (Ma et al., 2015; Outhred et al., 
2014a), the present pharmacogenetic-fMRI study found that ‘L’ alleles were associated 
with a negative L amygdala-R IFG functional connectivity during reappraisal with 
escitalopram, which may reflect regulation of amygdala responses during processing of 
negative stimuli (Aron et al., 2004; Banks et al., 2007; Goldin et al., 2008; Ochsner and 
Gross, 2005). These observations suggest that, in those with more ‘L’ alleles, a single 
dose of a commonly prescribed SSRI facilitates a positive information bias through 
emotion regulation circuitry, consistent with cognitive neuropsychological models of 
antidepressant action (Harmer et al., 2009; Outhred et al., 2014b; 2014a; 2013; Pringle 
et al., 2011; Roiser et al., 2012). Additionally, in probing the serotonergic system with 
an acute dose of an SSRI, we provide in vivo support for Hariri and Holmes’s (2006) 
model of 5-HTTLPR and emotion regulation circuitry in that 5-HTTLPR accounted for 
variation in circuitry response to 5-HT augmentation. Acute improvement in cognitive 
neuropsychological processes with antidepressant treatment may form the basis for 
downstream changes and symptom amelioration with clinical therapeutic administration 
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seen not only until after weeks of treatment (Harmer et al., 2009; Pringle et al., 2011; 
Roiser et al., 2012). Though acute SSRI administration has measurable neural effects, 
the manner in which these translate to clinical benefits is yet to be fully elucidated; 
however, it is speculated that facilitation and use of more adaptive emotional regulation 
strategies within the environment, along with reducing negative emotion processing 
bias, leads to improved mood symptoms overtime, inline with cognitive models of 
affective disorder (Beck, 2008; Beck et al., 1979; Gotlib and Joormann, 2010). The 
present findings suggest emotion regulation-related neural processing may improve with 
more ‘L’ alleles; thus providing a potential, at least partial, explanation for the manner 
in which more ‘L’ alleles predicts improved response to, and remission with 
antidepressant treatment (Kato and Serretti, 2010; Licinio and Wong, 2011; Ruhé et al., 
2009; Serretti et al., 2007). Hence, future research should examine whether differential 
acute effects of antidepressants on emotion regulation associated with 5-HTTLPR 
variation are predictive of longitudinal therapeutic changes with chronic treatment in 
patients with affective disorders. Given that 5-HTT is a target of antidepressants at 
which initial changes occur, 5-HTTLPR is a likely candidate for explaining variation in 
treatment outcomes (Licinio and Wong, 2011). However, 5-HTTLPR alone is unlikely 
to predict the downstream changes that occur with chronic, therapeutic administration. 
Additional candidate genes accounting for downstream changes include those involved 
in the expression of neurotropic factors such as brain derived neurotrophic factor 
(BDNF) Val66Met (Chen et al., 2011). 
Based on the present study’s findings within the context of the aforementioned 
literature, a framework was developed for understanding the potential impact of 5-
HTTLPR on acute SSRI administration on differential change in emotional biases 
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though emotion regulation circuitry, having consequences for downstream changes and 
symptom amelioration over weeks of treatment (see Figure 2). Building on previous 
models (Harmer et al., 2009; Outhred et al., 2014b; 2014a; 2013; Pringle et al., 2011; 
Roiser et al., 2012), a potential mechanism is proposed as follows. 5-HTT expression 
plays a role in the manner in which increases in 5-HT with SSRI 5-HTT blockade are 
regulated, though the more subordinate cellular mechanism is undetermined (Ruhé et 
al., 2009). Decreased 5-HT levels in ‘S’ carriers with acute SSRI treatment in contrast 
to increased 5-HT levels in ‘L’ carriers are hypothesized to be related to differential 5-
HT1A autoreceptor sensitivity or 5-HT pooling, or both (Ruhé et al., 2009). Regardless, 
individuals with the low expressing ‘S’ allele have increased dysregulation of 5-HT 
with treatment leading to L amygdala-R IFG functional connectivity modulation 
consistent with an increased negative emotion bias. In contrast, those with the high 
expressing ‘L’ allele have increased regulation of 5-HT with treatment, leading to 
connectivity modulation consistent with an increased positive emotion bias. This 
mechanism may account for variation in downstream changes, symptom amelioration, 
and thus therapeutic treatment responses by 5-HTTLPR variation. In sum, the 
facilitation of functional connectivity between the L amygdala and R IFG—as an 
emotion regulation circuit—may be a key target of SSRIs, and differential modulation 
of this emotion regulation circuit with SSRIs may explain differential therapeutic 
outcomes between 5-HTTLPR groups. 
4.1 Limitations 
With the preliminary nature of the present study, a limitation was the small sub-
samples of the homozygote ‘S/S’ and ‘L/L’ 5-HTTLPR groupings. However, the 
within-subjects nature of the experiment—with both treatment and task conditions—and 
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observing the within-subjects changes at the individual subject level increases our 
confidence in the findings of the present study. A second possible limitation was that a 
female-only sample was employed, findings, therefore, may not generalize to the male 
population. While this can also be considered a strength, as gender differences in 
neurophysiological responses to affective stimuli (Kemp et al., 2004b; Kret and De 
Gelder, 2012) and antidepressant administration (Khan et al., 2005; Young et al., 2009) 
are widely reported, future studies need to investigate whether similar effects are 
observed in males. Nevertheless, the employment of a homogenous, well-characterized 
sample within-subjects design and extensive manipulation checks (see Supplement), 
along with, increase our confidence in the observed findings. Examining responses 
within healthy and homogenous samples enables a high degree of control, and these 
findings will inform future studies in clinical populations, with both acute and long-term 
treatment. While the gPPI analysis provided important insights into functional 
connectivity modulation, causal inferences cannot be made and modulations maybe 
mediated by other regions or pathways. While 5-HTTLPR accounts for expression in 
the 5-HTT SSRI target, other variation on other genes are likely to account for 
responses, particularly with longer-term treatment and downstream changes. 
4.2 Conclusion 
We believe this is the first study to demonstrate a pharmacogenetic effect within 
the brain’s emotion regulation circuitry following a single dose of the commonly 
prescribed SSRI escitalopram. Variation in acute neural changes with SSRI treatment 
facilitates reappraisal of negative stimuli, an effect that may, in part, be explained by 5-
HTTLPR. Specifically, the ‘S’ allele was related to modulation of L amygdala-R IFG 
activity consistent with emotion dysregulation, while the ‘L’ allele related to L 
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amygdala-R IFG activity consistent with improved emotion regulation. Though 
preliminary, these findings are likely to extend the understanding of the 
pharmacogenetics of acute SSRI treatment in that a foundation on which future research 
in clinical samples could be based was provided. Extrapolation of this work into the 
clinical arena and further study of the pharmacogenetics of antidepressant treatment at 
acute and chronic stages in patient samples will provide important leads towards 
personalized medicine in affective disorders. 
Supplementary materials 
Supplementary data to this article can be found online at <url> 
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Table 1 
Participant demographics and functional connectivity change with treatment by 5-
HTTLPR group 
 
5-HTTLPR 
 
 ‘S/S’  
(n = 8) 
 ‘S/L’  
(n = 21) 
 ‘L/L’  
(n = 7) 
Group 
Differences 
Age  
(years; SD) 
22.50 
(3.67) 
 
24.95 
(6.32) 
 
28.43 
(8.66) 
F(2, 33) = 1.623 
p = 0.213 
Education  
(years; SD) 
16.88 
(3.14) 
 
16.95 
(2.67) 
 
18.14 
(3.02) 
F(2, 33) = 0.514 
p = 0.603 
BMI  
(kg/m2; SD) 
21.79 
(2.54) 
 
22.88 
(3.17) 
 
21.64 
(2.30) 
F(2, 33) = 0.708 
p = 0.500 
PHQ-9  
(SD) 
1.75 
(1.04) 
 
1.48 
(1.21) 
 
1.00 
(1.00) 
F(2, 33) = 0.830 
p = 0.445 
GAD-7  
(SD) 
1.00 
(1.15) 
 
1.10 
(1.14) 
 
1.14 
(0.90) 
F(2, 33) = 0.029 
p = 0.971 
Functional 
Connectivity (gPPI Δ) 
1.72 
(1.15) 
 
-0.69 
(1.34) 
 
-0.96 
(0.88) 
F(2, 33) = 12.792 
p < 0.001 
       
Note. SD = standard deviation; BMI = body mass index; PHQ-9 = Patient Health 
Questionnaire; GAD-7 = Generalized Anxiety Disorder questionnaire; gPPI Δ = 
generalized psychophysiological interaction change with treatment: PPI escitalopram – 
PPI placebo beta coupling estimates (positive values = decreased negative connectivity 
with escitalopram; negative values = increased negative connectivity with 
escitalopram).   
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Figure 1. The impact of 5-HTTLPR on functional connectivity (gPPI) between the left 
amygdala seed and the right inferior frontal gyrus target during reappraisal of negative 
stimuli under escitalopram treatment. Panel A. The L amygdala seed region (6 mm 
sphere at [-20 , -4, -20]). Panel B. The cluster activation of the right inferior frontal 
gyrus negatively correlated with left amygdala activation during reappraisal under 
escitalopram treatment. Panel C. Average beta coupling estimates under each treatment 
session for the whole sample (N = 36, as reported in Outhred et al., 2015), and then split 
by 5-HTTLPR groups (for the present study). Panel D. The negative relationship 
between ‘L’ alleles and functional connectivity signal change during reappraisal of 
negative images with escitalopram treatment (dashed lines represent the 95% 
confidence interval of the regression slope). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 is attached separately.
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Figure 2. An extended framework for understanding the impact of 5-HTTLPR on acute 
SSRI administration on differential change in emotional biases though emotion 
regulation circuitry, having consequences for downstream changes and symptom 
amelioration. 5-HTT expression plays a role in the manner in which increases in 5-HT 
with SSRI 5-HTT blockade are regulated. Individuals with low expressing ‘S’ allele 
have increased dysregulation of 5-HT with treatment leading to modulation of emotion 
regulation circuitry consistent with an increased negative emotion bias. In contrast, 
those with the high expressing ‘L’ allele have increased regulation of 5-HT with 
treatment, leading to modulation of emotion regulation circuitry consistent with an 
increased positive emotion bias. The facilitation of functional connectivity between the 
L amygdala and the R IFG is a key target of SSRIs (rather than modulation of each 
region themselves; shown in white). Further, the differential modulation of the emotion 
regulation circuit with SSRIs thus explains differential therapeutic outcomes between 5-
HTTLPR groups. 
 
 
 
 
 
 
 
 
 
Figure 2 is attached separately 
